Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2023-02-15 00:00:00 ET · period of report 2023-02-13 · accession 0001662579-23-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-15 | 2023-02-13 | CCCC | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +20.0K | 25.2K | +386% | $0 |
| D | 2023-02-15 | 2023-02-13 | CCCC | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +90.0K | 90.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-13 | A | A | 20,000 | $0.00 | 25,176 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-13 | A | A | 90,000 | $0.00 | 90,000 | D | $5.67 · — to 2033-02-12 | 90,000 Common Stock | (F2) The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. |